Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy

James M. Pluda, David J. Venzon, Giovanna Tosato, Jill Lietzau, Kathleen Wyvill, David L. Nelson, Elaine S. Jaffe, Judith Karp, Samuel Broder, Robert Yarchoan

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate the occurrence of non-Hodgkin's lymphoma (NHL) in human immunodeficiency virus (HIV)-infected patients receiving long-term antiretroviral therapy and factors associated with the development of these lymphomas. Patients and Methods: The charts of 55 patients with advanced HIV infection receiving zidovudine (formerly known as azidothymidine [AZT])-based therapy and 61 patients receiving dideoxyinosine (ddl) were examined for the occurrence of NHL. Stored samples from the AZT-based treatment cohort were examined retrospectively for parameters predictive of the subsequent development of lymphoma. Results: Eight of 55 patients receiving AZT-based therapy developed NHL, yielding an estimated probability of 12% (95% confidence interval [CI], 4.7% to 27.1 %) after 24 months, and 29.2% (95% CI, 15.2% to 48.7%) after 36 months. Four of 61 patients receiving ddl developed NHL, yielding a 6.2% (95% CI, 2.1% to 17%) estimated probability after 24 months, and 9.5% (95% Cl, 3.6% to 22.8%) after 36 months. The difference between these cohorts was not significant (two-tailed P [P2] = .13). Patients with less than 50 CD4 cells/μL developed NHL at a significantly higher rate (P2 = .0085). This was particularly true for patients who presented with primary CNS lymphoma (PCNSL). For patients receiving AZT-based therapy, pretreatment serum interleukin-6 (IL-6) levels were somewhat higher in those who subsequently developed NHL than in those who did not (P2 = .048). Conclusion: HIV-infected patients with profound immunodeficiency, especially those with less than 50 CD4 cells/μL, are at substantial risk of developing NHL and particularly PCNSL. Additional studies are needed to define the role of other factors such as IL-6 in the pathogenesis of these opportunistic tumors.

Original languageEnglish (US)
Pages (from-to)1099-1107
Number of pages9
JournalJournal of Clinical Oncology
Volume11
Issue number6
StatePublished - 1993
Externally publishedYes

Fingerprint

Virus Diseases
Non-Hodgkin's Lymphoma
HIV
Zidovudine
Lymphoma
Therapeutics
Confidence Intervals
Interleukin-6
Didanosine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pluda, J. M., Venzon, D. J., Tosato, G., Lietzau, J., Wyvill, K., Nelson, D. L., ... Yarchoan, R. (1993). Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. Journal of Clinical Oncology, 11(6), 1099-1107.

Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. / Pluda, James M.; Venzon, David J.; Tosato, Giovanna; Lietzau, Jill; Wyvill, Kathleen; Nelson, David L.; Jaffe, Elaine S.; Karp, Judith; Broder, Samuel; Yarchoan, Robert.

In: Journal of Clinical Oncology, Vol. 11, No. 6, 1993, p. 1099-1107.

Research output: Contribution to journalArticle

Pluda, JM, Venzon, DJ, Tosato, G, Lietzau, J, Wyvill, K, Nelson, DL, Jaffe, ES, Karp, J, Broder, S & Yarchoan, R 1993, 'Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy', Journal of Clinical Oncology, vol. 11, no. 6, pp. 1099-1107.
Pluda, James M. ; Venzon, David J. ; Tosato, Giovanna ; Lietzau, Jill ; Wyvill, Kathleen ; Nelson, David L. ; Jaffe, Elaine S. ; Karp, Judith ; Broder, Samuel ; Yarchoan, Robert. / Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 6. pp. 1099-1107.
@article{8e517f5ea0f4496b93f3855b70963edb,
title = "Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy",
abstract = "Purpose: To investigate the occurrence of non-Hodgkin's lymphoma (NHL) in human immunodeficiency virus (HIV)-infected patients receiving long-term antiretroviral therapy and factors associated with the development of these lymphomas. Patients and Methods: The charts of 55 patients with advanced HIV infection receiving zidovudine (formerly known as azidothymidine [AZT])-based therapy and 61 patients receiving dideoxyinosine (ddl) were examined for the occurrence of NHL. Stored samples from the AZT-based treatment cohort were examined retrospectively for parameters predictive of the subsequent development of lymphoma. Results: Eight of 55 patients receiving AZT-based therapy developed NHL, yielding an estimated probability of 12{\%} (95{\%} confidence interval [CI], 4.7{\%} to 27.1 {\%}) after 24 months, and 29.2{\%} (95{\%} CI, 15.2{\%} to 48.7{\%}) after 36 months. Four of 61 patients receiving ddl developed NHL, yielding a 6.2{\%} (95{\%} CI, 2.1{\%} to 17{\%}) estimated probability after 24 months, and 9.5{\%} (95{\%} Cl, 3.6{\%} to 22.8{\%}) after 36 months. The difference between these cohorts was not significant (two-tailed P [P2] = .13). Patients with less than 50 CD4 cells/μL developed NHL at a significantly higher rate (P2 = .0085). This was particularly true for patients who presented with primary CNS lymphoma (PCNSL). For patients receiving AZT-based therapy, pretreatment serum interleukin-6 (IL-6) levels were somewhat higher in those who subsequently developed NHL than in those who did not (P2 = .048). Conclusion: HIV-infected patients with profound immunodeficiency, especially those with less than 50 CD4 cells/μL, are at substantial risk of developing NHL and particularly PCNSL. Additional studies are needed to define the role of other factors such as IL-6 in the pathogenesis of these opportunistic tumors.",
author = "Pluda, {James M.} and Venzon, {David J.} and Giovanna Tosato and Jill Lietzau and Kathleen Wyvill and Nelson, {David L.} and Jaffe, {Elaine S.} and Judith Karp and Samuel Broder and Robert Yarchoan",
year = "1993",
language = "English (US)",
volume = "11",
pages = "1099--1107",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy

AU - Pluda, James M.

AU - Venzon, David J.

AU - Tosato, Giovanna

AU - Lietzau, Jill

AU - Wyvill, Kathleen

AU - Nelson, David L.

AU - Jaffe, Elaine S.

AU - Karp, Judith

AU - Broder, Samuel

AU - Yarchoan, Robert

PY - 1993

Y1 - 1993

N2 - Purpose: To investigate the occurrence of non-Hodgkin's lymphoma (NHL) in human immunodeficiency virus (HIV)-infected patients receiving long-term antiretroviral therapy and factors associated with the development of these lymphomas. Patients and Methods: The charts of 55 patients with advanced HIV infection receiving zidovudine (formerly known as azidothymidine [AZT])-based therapy and 61 patients receiving dideoxyinosine (ddl) were examined for the occurrence of NHL. Stored samples from the AZT-based treatment cohort were examined retrospectively for parameters predictive of the subsequent development of lymphoma. Results: Eight of 55 patients receiving AZT-based therapy developed NHL, yielding an estimated probability of 12% (95% confidence interval [CI], 4.7% to 27.1 %) after 24 months, and 29.2% (95% CI, 15.2% to 48.7%) after 36 months. Four of 61 patients receiving ddl developed NHL, yielding a 6.2% (95% CI, 2.1% to 17%) estimated probability after 24 months, and 9.5% (95% Cl, 3.6% to 22.8%) after 36 months. The difference between these cohorts was not significant (two-tailed P [P2] = .13). Patients with less than 50 CD4 cells/μL developed NHL at a significantly higher rate (P2 = .0085). This was particularly true for patients who presented with primary CNS lymphoma (PCNSL). For patients receiving AZT-based therapy, pretreatment serum interleukin-6 (IL-6) levels were somewhat higher in those who subsequently developed NHL than in those who did not (P2 = .048). Conclusion: HIV-infected patients with profound immunodeficiency, especially those with less than 50 CD4 cells/μL, are at substantial risk of developing NHL and particularly PCNSL. Additional studies are needed to define the role of other factors such as IL-6 in the pathogenesis of these opportunistic tumors.

AB - Purpose: To investigate the occurrence of non-Hodgkin's lymphoma (NHL) in human immunodeficiency virus (HIV)-infected patients receiving long-term antiretroviral therapy and factors associated with the development of these lymphomas. Patients and Methods: The charts of 55 patients with advanced HIV infection receiving zidovudine (formerly known as azidothymidine [AZT])-based therapy and 61 patients receiving dideoxyinosine (ddl) were examined for the occurrence of NHL. Stored samples from the AZT-based treatment cohort were examined retrospectively for parameters predictive of the subsequent development of lymphoma. Results: Eight of 55 patients receiving AZT-based therapy developed NHL, yielding an estimated probability of 12% (95% confidence interval [CI], 4.7% to 27.1 %) after 24 months, and 29.2% (95% CI, 15.2% to 48.7%) after 36 months. Four of 61 patients receiving ddl developed NHL, yielding a 6.2% (95% CI, 2.1% to 17%) estimated probability after 24 months, and 9.5% (95% Cl, 3.6% to 22.8%) after 36 months. The difference between these cohorts was not significant (two-tailed P [P2] = .13). Patients with less than 50 CD4 cells/μL developed NHL at a significantly higher rate (P2 = .0085). This was particularly true for patients who presented with primary CNS lymphoma (PCNSL). For patients receiving AZT-based therapy, pretreatment serum interleukin-6 (IL-6) levels were somewhat higher in those who subsequently developed NHL than in those who did not (P2 = .048). Conclusion: HIV-infected patients with profound immunodeficiency, especially those with less than 50 CD4 cells/μL, are at substantial risk of developing NHL and particularly PCNSL. Additional studies are needed to define the role of other factors such as IL-6 in the pathogenesis of these opportunistic tumors.

UR - http://www.scopus.com/inward/record.url?scp=0027210354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027210354&partnerID=8YFLogxK

M3 - Article

C2 - 8099121

AN - SCOPUS:0027210354

VL - 11

SP - 1099

EP - 1107

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -